Examining the effect of SARS-CoV-2 pandemic-induced stress and anxiety on humoral immunity in healthcare workers.
Journal
Journal of occupational and environmental medicine
ISSN: 1536-5948
Titre abrégé: J Occup Environ Med
Pays: United States
ID NLM: 9504688
Informations de publication
Date de publication:
23 Nov 2023
23 Nov 2023
Historique:
medline:
28
11
2023
pubmed:
28
11
2023
entrez:
28
11
2023
Statut:
aheadofprint
Résumé
The effect of stress on vaccine-induced humoral immunity and therapeutic interventions to mitigate pandemic-related stress remain under-explored. Participants in a longitudinal cohort study (n = 189) completed a validated measure, 7-instrument Generalized Anxiety Disorder (GAD-7), and 10-instrument stress measure (SM-10) to assess stress and anxiety following SARS-CoV-2 vaccination. Serum was collected to obtain SARS-CoV-2 antibody titer levels. Participants experienced increased stress due to the SARS-CoV-2 pandemic with a positive correlation between GAD-7 scores and peak antibody (Ab) titers overall; however, there was a negative association with scores commensurate with severe anxiety. Healthcare workers (HCW) and younger participants were more significantly affected by anxiety. Mild anxiety levels may have immune-enhancing effects, whereas severe anxiety may cause antibody generation reduction. Mental health-focused interventions are imperative for younger adults and HCWs. Young adults may be more resilient to increased stress levels.
Identifiants
pubmed: 38013399
doi: 10.1097/JOM.0000000000003014
pii: 00043764-990000000-00453
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American College of Occupational and Environmental Medicine.
Déclaration de conflit d'intérêts
Conflict of Interest: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020) which list Florian Krammer as co-inventor. Patent applications were submitted by the Icahn School of Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Third Rock Ventures, GSK and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.